Patents by Inventor Yajing Rong
Yajing Rong has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 8759352Abstract: The present invention relates to 1-(4-ureidobenzoyl)piperazine derivatives having the general Formula I (We bring to your attention that formula I is not provided on this electronic version as it is provided in the abstract of the paper copy) Wherein R1 is (C1-8)alkyl, (C3-8)cycloalkyl or (C3-8)cycloalkyl(C1-3)alkyl, each of which may be substituted by hydroxy, cyano or halogen; R2 represents 1 or 2 optional halogens; R3 is (C1-6)alkyl, (C3-6)cycloalkyl or (C3-6)cycloalkyl(C1-3)alkyl, each of which may be substituted by one or more halogens; A represents a heteroaryl ring system comprising 1-3 heteroatoms selected from N, O and S, which ring system is 5- or 6-membered when X is C, and 5-membered when X is N; n is 1 or 2; or a pharmaceutically acceptable salt thereof; to pharmaceutical compositions comprising the same, and to the use of a these 1-(4-ureidobenzoyl)piperazine derivatives for the manufacture of a medicament for treating or preventing atherosclerosis and related disorders associated with cholesterType: GrantFiled: August 26, 2009Date of Patent: June 24, 2014Assignees: Merck Sharp & Dohme B.V., Pharmacopeia LLC.Inventors: Andrew John Cooke, David Jonathan Bennett, Andrew Stanley Edwards, Andrew Laird Roughton, Irina Neagu, Jui-Hsiang Chan, Koc-Kan Ho, Nasrin Ansari, Michelle Lee Morris, Yajing Rong, Michael Ohlmeyer
-
Patent number: 8314091Abstract: The present invention relates to N-benzyl,N?-arylcarbonylpiperazine derivatives having the general formula I to pharmaceutical compositions comprising the same, and to the use of a these N-benzyl,N?-arylcarbonylpiperazine derivatives for the manufacture of a medicament for treating or preventing atherosclerosis and related disorders associated with cholesterol and bile acids transport and metabolism.Type: GrantFiled: August 19, 2008Date of Patent: November 20, 2012Assignees: MSD OSS B.V., Pharmacopeia, Inc.Inventors: Koc-Kan Ho, Andrew Laird Roughton, Irina Neagu, Jui-Hsiang Chan, Nasrin Ansari, Michelle Lee Morris, Yajing Rong, Michael Ohlmeyer, Andrew John Cooke, Andrew Stanley Edwards, David Jonathan Bennett
-
Patent number: 8211927Abstract: The present invention relates to isoxazole-3-carboxamide derivative having the general Formula (I), or a pharmaceutically acceptable salt thereof, to pharmaceutical compositions comprising the same, as well as to the use of said isoxazole-3-carboxamide derivatives for the treatment of TRPV1 mediated disorders, such as acute and chronic pain disorders, acute and chronic neuropathic pain, acute and chronic inflammatory pain, respiratory diseases, and lower urinary tract disorders.Type: GrantFiled: July 31, 2008Date of Patent: July 3, 2012Assignee: MSD, Oss B.V.Inventors: Andrew Laird Roughton, Koc-Kan Ho, Michael Ohlmeyer, Irina Neagu, Steven G. Kultgen, Nasrin Ansari, Yajing Rong, Paul David Ratcliffe, Ronald Palin
-
Publication number: 20120015958Abstract: The present invention relates to 1-(4-ureidobenzoyl)piperazine derivatives having the general Formula I (We bring to your attention that formula I is not provided on this electronic version as it is provided in the abstract of the paper copy) Wherein R1 is (C1-8)alkyl, (C3-8)cycloalkyl or (C3-8)cycloalkyl(C1-3)alkyl, each of which may be substituted by hydroxy, cyano or halogen; R2 represents 1 or 2 optional halogens; R3 is (C1-6)alkyl, (C3-6)cycloalkyl or (C3-6)cycloalkyl(C1-3)alkyl, each of which may be substituted by one or more halogens; A represents a heteroaryl ring system comprising 1-3 heteroatoms selected from N, O and S, which ring system is 5- or 6-membered when X is C, and 5-membered when X is N; n is 1 or 2; or a pharmaceutically acceptable salt thereof; to pharmaceutical compositions comprising the same, and to the use of a these 1-(4-ureidobenzoyl)piperazine derivatives for the manufacture of a medicament for treating or preventing atherosclerosis and related disorders associated with cholesterType: ApplicationFiled: August 26, 2009Publication date: January 19, 2012Inventors: Andrew John Cooke, David Jonathan Bennett, Andrew Stanley Edwards, Andrew Laird Roughton, Irina Neagu, Jui-Hsiang Chan, Koc Kan Ho, Nasrin Ansari, Michelle Lee Morris, Yajing Rong, Michael Ohlmeyer
-
Patent number: 7989459Abstract: A chemical genus of purinones and 1H-imidazopyridinones, which are useful as PKC?. inhibitors, and their methods of use are disclosed. The genus is represented by the formula I: wherein R1 is chosen from nitrogen-attached heterocyclyl, nitrogen-attached substituted heterocyclyl wherein the point of attachment is a nitrogen heteroatom, and R2 is chosen from aryl, substituted aryl, arylalkyl, substituted arylalkyl, heteroaryl, substituted heteroaryl, hetroarylalkyl, and substituted heteroarylalkyl.Type: GrantFiled: February 2, 2007Date of Patent: August 2, 2011Assignee: Pharmacopeia, LLCInventors: Andrew Roughton, Yajing Rong, Koc Kan Ho, Michael Ohlmeyer, David Diller
-
Publication number: 20110065764Abstract: The present invention relates to isoxazole-3-carboxamide derivative having the general Formula (I), or a pharmaceutically acceptable salt thereof, to pharmaceutical compositions comprising the same, as well as to the use of said isoxazole-3-carboxamide derivatives for the treatment of TRPV1 mediated disorders, such as acute and chronic pain disorders, acute and chronic neuropathic pain, acute and chronic inflammatory pain, respiratory diseases, and lower urinary tract disorders.Type: ApplicationFiled: July 31, 2008Publication date: March 17, 2011Applicant: N.V. ORGANON AND PHARMACOPEIA, LLCInventors: Andrew Laird Roughton, Koc-Kan Ho, Michael Ohlmeyer, Irina Neagu, Steven G. Kultgen, Nasrin Ansari, Yajing Rong, Paul David Ratcliffe, Ronald Palin
-
Publication number: 20100004236Abstract: PDE4 inhibition is achieved by novel compounds of the Formula I: wherein R1 and R2 are as defined herein.Type: ApplicationFiled: February 26, 2009Publication date: January 7, 2010Inventors: Ashok Tehim, Allen T. Hopper, Ruiping Liu, Hans-Juregen Ernst Hess, Yajing Rong
-
Publication number: 20090281075Abstract: A chemical genus of purinones and 1H-imidazopyridinones, which are useful as PKC? inhibitors, and their methods of use are disclosed.Type: ApplicationFiled: November 7, 2008Publication date: November 12, 2009Applicant: PHARMACOPEIA, INC.Inventors: Andrew L. Roughton, Yajing Rong, Koc-Kan Ho, Michael J. Ohlmeyer, David Diller, Ray Jui-Hsiang Chan, Gaifa Lai
-
Publication number: 20090264416Abstract: The present invention relates to N-benzyl,N?-arylcarbonylpiperazine derivatives having the general formula I to pharmaceutical compositions comprising the same, and to the use of a these N-benzyl,N?-arylcarbonylpiperazine derivatives for the manufacture of a medicament for treating or preventing atherosclerosis and related disorders associated with cholesterol and bile acids transport and metabolism.Type: ApplicationFiled: August 19, 2008Publication date: October 22, 2009Inventors: Koc-Kan Ho, Andrew Laird Roughton, Irina Neagu, Jui-Hsiang Chan, Nasrin Ansari, Michelle Lee Morris, Yajing Rong, Michael Ohlmeyer, Andrew John Cooke, Andrew Stanley Edwards, David Jonathan Bennett
-
Publication number: 20080139583Abstract: PDE4 inhibition is achieved by novel compounds of the Formula I: wherein R1 and R2 are as defined herein.Type: ApplicationFiled: February 5, 2008Publication date: June 12, 2008Inventors: Ashok Tehim, Allen T. HOPPER, Ruiping Liu, Hans-Jurgen Ernst Hess, Yajing Rong
-
Publication number: 20080119495Abstract: PDE4 inhibition is achieved by novel compounds of the Formula I: wherein R1 and R2 are as defined herein.Type: ApplicationFiled: December 14, 2007Publication date: May 22, 2008Inventors: Ruiping LIU, Hans-Jurgen Ernst Hess, Allen Hopper, Ashok Tehim, Yajing Rong
-
Publication number: 20080085909Abstract: A chemical genus of purinones and 1H-imidazopyridinones, which are useful as PKC? inhibitors, and their methods of use are disclosed.Type: ApplicationFiled: February 2, 2007Publication date: April 10, 2008Applicant: Pharmacopeia Drug Discovery, Inc.Inventors: Andrew Roughton, Yajing Rong, Koc Kan Ho, Michael Ohlmeyer, David Diller
-
Patent number: 7342021Abstract: PDE4 inhibition is achieved by novel compounds of the Formula I: wherein R1 and R2 are as defined herein.Type: GrantFiled: February 8, 2002Date of Patent: March 11, 2008Assignee: Memory Pharmaceuticals Corp.Inventors: Ruiping Liu, Hans-Jurgen Ernst Hess, Allen Hopper, Ashok Tehim, Yajing Rong
-
Patent number: 7332486Abstract: PDE4 inhibition is achieved by novel compounds of the Formula I: wherein R1 and R2 are as defined herein.Type: GrantFiled: August 8, 2003Date of Patent: February 19, 2008Assignee: Memory Pharmaceuticals Corp.Inventors: Ashok Tehim, Allen T. Hopper, Ruiping Liu, Hans-Jurgen Ernst Hess, Yajing Rong
-
Publication number: 20070093510Abstract: PDE4 inhibition is achieved by novel compounds of the Formula I: wherein R1 and R2 are as defined herein.Type: ApplicationFiled: August 8, 2003Publication date: April 26, 2007Applicant: MEMORY PHARMACEUTICALS CORP.Inventors: Ashok Tehim, Allen Hopper, Ruiping Liu, Hans-Jurgen Hess, Yajing Rong
-
Publication number: 20040242598Abstract: PDE4 inhibition is achieved by novel compounds of the Formula I: 1Type: ApplicationFiled: May 14, 2004Publication date: December 2, 2004Inventors: Ruiping Liu, Hans-Jurgen Ernst Hess, Allen Hopper, Ashok Tehim, Yajing Rong
-
Patent number: 6794405Abstract: Alicyclic imidazole compounds; pharmaceutically active compositions containing such compounds; and the use of such compounds in formulations for the control or prevention of disease states in which histamine H3 receptors are involved, such as allergy, inflammation, hypotension, glaucoma, sleeping disorders, states of hyper- and hypo-motility of the gastro-intestinal tract, cardiovascular disease, hypo- and hyper-activity of the central nervous system, Alzheimer's, schizophrenia, obesity and migraines are disclosed.Type: GrantFiled: August 4, 2003Date of Patent: September 21, 2004Assignee: Merck & Co., Inc.Inventors: Yajing Rong, Jack B. Jiang, Syed M. Ali
-
Publication number: 20040029943Abstract: Alicyclic imidazole compounds; pharmaceutically active compositions containing such compounds; and the use of such compounds in formulations for the control or prevention of disease states in which histamine H3 receptors are involved, such as allergy, inflammation, hypotension, glaucoma, sleeping disorders, states of hyper- and hypo-motility of the gastro-intestinal tract, cardiovascular disease, hypo- and hyper-activity of the central nervous system, Alzheimer's, schizophrenia, obesity and migraines are disclosed.Type: ApplicationFiled: August 4, 2003Publication date: February 12, 2004Inventors: Yajing Rong, Jack B. Jiang, Syed M. Ali
-
Publication number: 20030045533Abstract: PDE4 inhibition is achieved by novel compounds of the Formula I: 1Type: ApplicationFiled: February 8, 2002Publication date: March 6, 2003Applicant: MEMORY PHARMACEUTICALS CORP.Inventors: Ruiping Liu, Hans-Jurgen Ernst Hess, Allen Hopper, Ashok Tehim, Yajing Rong
-
Publication number: 20020042400Abstract: Alicyclic imidazole compounds; pharmaceutically active compositions containing such compounds; and the use of such compounds in formulations for the control or prevention of disease states in which histamine H3 receptors are involved, such as allergy, inflammation, hypotension, glaucoma, sleeping disorders, states of hyper- and hypo-motility of the gastro-intestinal tract, cardiovascular disease, hypo- and hyper-activity of the central nervous system, Alzheimer's, schizophrenia, obesity and migraines are disclosed.Type: ApplicationFiled: August 15, 2001Publication date: April 11, 2002Inventors: Yajing Rong, Jack B. Jiang, Ali M. Syed